March 1, 2022
SAN FRANCISCO --(BUSINESS WIRE)--Mar. 1, 2022-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will
January 24, 2022
Topline Data from CAHmelia-203 and CAHmelia-204 Anticipated in 2H 2023 and 2H 2024, Respectively Strategic Reprioritization Extends Anticipated Cash Runway by 6 Months into Q2 2024 CAHmelia Program in Adult Classic CAH to Significantly Expand Sites Globally, Planned Increase of Up to 50 New Sites
Displaying 11 - 15 of 15